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Neuropathic pain is a common phenomenon that affects millions of people worldwide. Maxillofacial structures consist of various
tissues that receive frequent stimulation during food digestion. The unique functions (masticatory process and facial expression)
of the maxillofacial structure require the exquisite organization of both the peripheral and central nervous systems. Neuralgia is
painful paroxysmal disorder of the head-neck region characterized by some commonly shared features such as the unilateral pain,
transience and recurrence of attacks, and superficial and shock-like pain at a trigger point. These types of pain can be experienced
after nerve injury or as a part of diseases that affect peripheral and central nerve function, or they can be psychological. Since
the trigeminal and glossopharyngeal nerves innervate the oral structure, trigeminal and glossopharyngeal neuralgia are the most
common syndromes following myofascial pain dysfunction syndrome. Nevertheless, misdiagnoses are common. The aim of this
review is to discuss the currently available diagnostic procedures and treatment options for trigeminal neuralgia, glossopharyngeal
neuralgia, and myofascial pain dysfunction syndrome.
1. Introduction
Neuralgia is known as pain that occurs in the nerve pathways.
Usually, neuralgia is not a sickness but a symptom of an
injury or a disorder. Pain in the maxillofacial region exhibits
medical, dental, social, and psychological burdens. Maxillo-
facial pain originates from many sole target tissues such as
the meninges, cornea, tooth pulp, oral/nasal mucosa, and
temporomandibular joint, thus showing numerous unique
physiological features associated with the spinal nociceptive
system [1].Maxillofacial pain disorders cover amajor remark-
able and extensive part of neurological disorders and collec-
tively have a high occurrence rate and an often overwhelming
influence on the quality of life [2].
Although there are several common features of pain
transduction and processing between the trigeminal and
spinal nerve systems, numerous characteristic features in the
peripheral and central components of the trigeminal pain
system exist. Trigeminal neuralgia (TN) is the incidence of
uncontrollable and electrical stun-like pain with a trigger
zone, while glossopharyngeal neuralgia (GPN) is considered
as pain in the oropharyngeal area throughout themandibular
actions, mainly deglutition [3, 4]. Myofascial pain dysfunc-
tion syndrome (MPDS) is categorized by extensive pain,
decreased pain relief, sleep disruption, exhaustion, psychoso-
matic distress, and chronic headache. Patients withMPDS are
identified based on the presence of numerous tender points
[5]. Consequently, current basic and clinical studies that focus
on acute and chronic maxillofacial pain need to realize the
unique features of the pain system and to advance and assess
better treatments for orofacial pain.
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Themost important obstruction of enhanced patient care
and translational research is the absence of approved diagnos-
tic criteria [6].The intricate innervation and function of facial
region assemblies make the diagnosis of facial pain and its
treatment very problematic and frustrating [7]. Patients with
long-lasting facial pain should be cautiously reevaluated and
clinically examined even after getting multiple treatments.
The situation is compounded when neuralgia, ear nose and
throat (ENT) diseases, dental pain, myofascial pain syn-
dromes, tumors, temporomandibular disorders (TMD), neu-
rovascular pain, or psychiatric diseases commonly present
with covering signs and symptoms. In addition, referred,
severe, and acute pain frequently makes the diagnosis more
challenging [7, 8]. However, most neuralgia conditions
demonstrate similar clinical features. Therefore, sequential
clinical examinations with additional laboratory diagnoses
are essential for the proper treatment and management of
such conditions [9].
An effective evidence-based management of neuralgic
pain requires a thorough appreciation of the underlying
mechanism of pain. In this review, we describe the updated
knowledge on the pathophysiology, clinical features, diagnos-
tic criteria, and management of TN, GPN, and MPDS.
2. Trigeminal Neuralgia
Trigeminal neuralgia is a unilateral disorder highlighted by
electric stun-like neuropathic pain near the distribution of
the trigeminal nerves with sudden onset and termination. It
is defined as a syndrome that is characterized by paroxysmal
facial pain. According to Loh et al. (1998), the affliction site
ratio was observed as 1.4 (right) : 1 (left) of the facial area [10].
The characteristics of TN include sudden, severe, periodic,
stabbing, lancinating, lightning-like, and shock-like pain
attacks that are usually one-sided in the 2nd and/or 3rd
trigeminal branch [11–13]. TN is one of the most common
neurological pains involving the orofacial region, which
generally has the most intensive type of pain [4, 14, 15]. It
typically affects the elderly (1 in 25,000 of the population),
with the most frequently reported cause being neurovascular
compression [16–18]. From an etiological aspect, TN is clas-
sified as classic or primary or idiopathic and symptomatic or
secondary. Classic or primaryTNappearswith no clear cause.
Symptomatic or secondary TN occurs with the presence of
intracranial lesions such as a tumor, infarction, and multiple
sclerosis (MS). From a symptomatic aspect, TN is classified as
“typical” in the presence of paroxysmal pain alone and “atyp-
ical” when the paroxysmal pain is associated with constant
pain [19].
Pain in 95% of the TN cases is almost unilateral, com-
monly affecting the mandibular and maxillary divisions [13].
According to Loh et al. (1998), there was a greater contri-
bution of the mandibular branch of the trigeminal nerve
than the maxillary branch in TN patients (𝑛 = 44) [10]. An
attack of TN is typically originated by a slightmucocutaneous
incentive in the region of the affected trigeminal nerve also
known as a trigger point [18, 19].The diagnosis of TN is based
on the typical case history of episodic electric pain in the
supply of the trigeminal nerve [20]. However, the diagnosis
and management of TN require a group of experts consisting
of neurologists, anesthesiologists, neurosurgeons, neuroradi-
ologists, oral andmaxillofacial surgeons, and dentists [21, 22].
2.1. Epidemiology. The prevalence of TN has been estimated
at 107.5 males and 200.2 females per 1 million populations
[23]. The incidence rate of TN was 4.3 per 100,000 in the
US population, with the age-adjusted rate for females being
significantly higher than that for males [24]. The predictable
frequency of TN is approximately 4–12.5/100,000 people
annually, with increasing occurrence based on stage [25].
Because age is a primary risk factor, symptom manifestation
is more likely after the age of 50 years [26]. The topmost
inception of TN occurs between the ages of 50 and 70 years,
but it can happen even at a younger age. A study reported the
usual age of sign onset at 19.6±3.4 years [27].Themost widely
recognized age group was 51 to 60 years (36.90%), followed
by 61 to 70 years (23.68%) and 41 to 50 years (17.35%) [28]. It
is unusual in individuals older than 30 years, with only 1% of
cases in thosemore youthful than 20 years of age [29, 30].The
annual occurrence in females is approximately 5.9/100,000
cases per females, while it is approximately 3.4/100,000 cases
per males [25, 31]. The female-to-male proportion of TN was
3 : 2 [32]. TN is more common among females (62%) than
amongmales (38%), with a female-to-male ratio of 1.6 : 1 [33].
Thus, females have a higher risk of having TN thanmales, and
the risk again increases with age [30].
In addition, a retrospective study of TN patients in Sin-
gapore and Malaysia revealed that the age of onset fluctuates
from 24 to 89 years with a mean age of 54.9 years. The
ultimate occurrence was in the 6th (29.5%) and 7th (27.3%)
decades of life, followed by the 5th decade (13.6%).The fourth
and eighth decades had similar incidences (11.4%). This was
followed by the third (4.5%) and ninth (2.3%) decades. With
respect to sexual orientation, females account for 63.7% of
the patients, with a ratio of 1.75 : 1.00. The distribution of TN
in multiethnic populations was 68.2% among the Chinese,
followed by 13.6% and 11.4% in Malays and Indians, respec-
tively. The remaining distribution was solitary Japanese and
two Eurasians [10].
Other than the age and gender, multiple sclerosis (MS) is
a well-known risk factor to TN [10, 27].MS has been reported
in 2 to 4% of patients with TN where demyelination is also
present [24]. The reported prevalence of TN in the MS
population was between 1.0% and 6.3% [34, 35]. In addition,
approximately 4% of MS patients have a lifetime risk to have
TN, with no significant difference observed among the dif-
ferent forms of MS [36]. Approximately 5% of idiopathic TN
cases have been reported to have a family history [33]. Hence,
older females, MS, and family history are important risk
factors for TN.
2.2. Pathophysiology. TN occurs due to the specific abnor-
malities of the trigeminal nerve in the trigeminal root or
ganglion. The pathophysiological characteristics of classic or
idiopathic TN are identified with the pressure of the trigem-
inal nerve root by a vein at or nearby the root passage zone
[17, 37, 38]. An artery crossing the nerve can provoke further
displacement [39], which can lead to damage and injury of
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the trigeminal nerve.The damage tends to be localized and is
specifically related to the vascular contact [40, 41]. The dam-
aged nerves cause pain via several mechanisms, including
the hyperexcitability of the demyelinated nerve fibers, ectopic
impulse discharge, spontaneous and triggered after discharge,
cross excitation between sensory channels, deafferentation,
impaired segmental inhibition, and emphatic transmission
[38, 40–43]. The vascular pressure of the trigeminal nerve
root is associated with the focal loss of myelin and the close
juxtaposition of the demyelinated axons with few mediating
astrocytic processes [40].
Symptomatic or secondary TN occurs due to intracra-
nial lesions such as a tumor, infarction, and MS [19, 44].
Intracranial tumors in the presence of aneurysms, angiomas,
or vascular malformation are among other causes of TN
[45, 46] that may occur by either direct tumoral compression
or the wrapping of the trigeminal nerve root [47, 48]. Tumor
occurrence has been reported to bemore common amongTN
patients aged less than 39 years than among those older than
40 years [49]. Approximately 2 to 4%ofMS has been reported
to occur in TN patients [24] as well.
2.3. Clinical Manifestation. The hallmark of TN includes
recurrent attacks of lancinating pain in the trigeminal nerve
[50]. The attacks typically last just seconds, yet they may be
repeated over and again inside a brief time frame. Approx-
imately 79% of the pain experienced is intermittent, while
21% of pain is continuous [13].The nature of pain is sporadic,
sudden, and often like an electric shock, enduring from a few
moments to a fewminutes [27]. In fact, TN has been reported
to be a relatively common pain condition, occurring more
commonly on the right side (72.63%) than on the left side
(27.37%) with a ratio of 2.6 : 1.0 [30, 51] and mainly affecting
the mandibular division [10, 30]. The communal outlying
nerve involved is infraorbital with various patients presented
with sensible pain [30].
The brief paroxysms pain in TN is restricted to the facial
conveyance of the trigeminal nerve and can be triggered by
stimuli to sensory endings in the trigeminal receptive area
[52]. The triggering stimuli include simple actions such as
talking, swallowing, laughing, washing, wind-blowing, shav-
ing, mouth opening, touching, and chewing. Nevertheless,
the presence of these triggering stimulimay cause the patients
to circumvent any stimulus on the face or mouth. Most
patients respond to different strengths of the aggravating
stimulus and react to more than a single triggering stimulus
[53].
2.4. Diagnostic Criteria. The diagnosis of TN basically relies
on a patient’s description of pathognomonic pain occurrences
[54]. The primary diagnostic tools are MRI (magnetic reso-
nance imaging) and CT (computed tomography), since there
is no specific laboratory test available (Table 4). Therefore,
patients’ signs and symptoms are key important factors in
making the diagnosis (Figure 1).
TN is generally idiopathic [55]; however, it might like-
wise emerge optional to different conditions, including the
intracranial space involving lesions andmultiple sclerosis [35,
56, 57]. The International Association for the Study of Pain
(IASP) and International Headache Society (IHS) has rec-
ommended their own indicative criteria for TN [58, 59]. The
IASP has defined the TN as a sudden, normally one-sided,
extremely brief cutting intermittent pain in the dissemination
of at least one branch of the fifth cranial nerve. On the
other hand, the IHS defines TN as an excruciating one-sided
distress of the face, described by brief electric stun-like pain
restricted to the circulation of at least one division of the
trigeminal nerve. Pain is usually induced by insignificant
stimuli, which include smoking, sneezing, and brushing the
teeth, all of which often regularly occur impulsively. Little
zones in the nasolabial fold and chin might be prone to the
precipitation of pain that may remit for variable periods [58].
According to Eller et al. (2005), TN is defined and clas-
sified into seven types: (i) TN1: idiopathic, sharp, shooting,
electrical shock-like, and episodic pain; (ii) TN2: idiopathic,
aching, throbbing, burning, and more than 50% constant
pain; (iii) TN3: trigeminal neuropathic pain and accidental
harm to the trigeminal nerve from injury or surgery (facial
trauma; oral operation; ear, nose, and throat operation; skull
base operation; posterior fossa operation; or stroke); (iv)
TN4: trigeminal deafferentation pain and intentional injury
to the trigeminal nerve (gangliolysis, nucleotomy, neurec-
tomy, tractotomy, rhizotomy, or other denervating proce-
dures); (v) TN5: symptomatic, associated with MS; (vi) TN6:
postherpetic because of a flare-up of facial herpes zoster;
and (vii) TN7: atypical facial pain and facial pain auxiliary
to a somatoform pain issue, requiring mental testing for
indicative diagnostic affirmation [32].
2.5. Treatment and Management. Table 1 presents various
pharmacological agents and available treatment options
based on surgical procedures. Bothmethods are effective and
widely used [60–62]. Usually, TN patients are first treated
with pharmacological agents. The pain can be readily man-
aged with medication in approximately 80% of patients [63].
However, if the pain is not effectively relieved by medications
or there is medication intolerance due to toxicity or allergic
reactions, surgical treatment becomes an option.
In standard practice, the first-line treatment is carba-
mazepine, which can relieve most of the observed symptoms
[22, 64–66]. Other drugs, including oxcarbazepine [67], phe-
nytoin [68, 69], baclofen [70, 71], lamotrigine [72, 73], gaba-
pentin [74, 75], and sodium valproate [76, 77], are also effi-
cient in reducing the signs-symptoms of TN inmost patients.
Sometimes, some of the drugs are taken with carbamazepine
as an adjuvant for the synergistic effects in relieving the
TN symptoms [78, 79]. The decreasing relief provided by
carbamazepine or other drugs with continual use as well as
unacceptable side effect profiles may necessitate the discon-
tinuation of therapy. In fact, it has been reported that approx-
imately 50% of patients eventually require an operation to
relieve pain [25]. Research has indicated that there is no
significant influence of age, sex, ethnicity, or the side of the
face on the decision of themedication regimen and the length
of treatment for pain control [79].
When drugs no longer offer pain relief, surgical interven-
tion is preferred. The objective of surgery procedures is to
prevent the blood vessel from squeezing the trigeminal nerve
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Unilateral orofacial pain/paroxysmal facial
TN
IHS
onset onset
Fifth
shock-sided
trigeminal nerve
Figure 1: The basic diagnostic criteria of trigeminal neuralgia (TN).
or injuring the trigeminal nerve. Several surgical approaches
used to relieve the pain due to TN include neurectomy of
trigeminal nerve branches outside the skull, percutaneous
radiofrequency thermal rhizotomy, percutaneous ablation
that creates trigeminal nerve or trigeminal ganglion lesions
with heat [80–82], percutaneous retrogasserian glycerol rhi-
zotomy, injection of glycerol into the trigeminal cistern
[62, 83, 84], physical compression, trigeminal ganglion bal-
loon microcompression [85], alcohol injections [57, 86],
botulinum toxin injection [87, 88], cryotherapy [89, 90], and
gamma-knife radiosurgery (GKRS) [91]. These procedures
are intended to alleviate the symptoms of TN by relieving
nerve compression at some point along its course. Hereafter,
the management of TN is dependent on a fast, correct diag-
nosis, prompt, and effective treatment because the symptoms
can be very severe.
2.6. Complications. Many drugs used in the treatment and
management of TN are associated with several side-effects.
Nevertheless, most of the effects can be tolerated and imme-
diate drug discontinuation is conducted when the common
pain tolerance level is exceeded. In addition, some of the
surgical procedures may contribute to some complications
such as microvascular decompression (MVD) which is able
to relieve an abnormal compression of an artery to the
trigeminal nerve. Although it is generally successful, achiev-
ing 70–90% pain control and less than 1% of the mortality
risk [92], the procedure may lead to hearing loss which
is associated with a refutation injury of cranial nerve VIII
[93]. Nevertheless, the complications were less common
following an intraoperative monitoring of the brainstem
evoked response.
The rate of ipsilateral hearing loss was 3% (previous
1980) and 1% thereafter (𝑝 = 0.008). Radiosurgery, which
can increase the pain control rate up to 83%, is effective
in treating TN [91]. Its complication rate is only 6% for
facial paresthesia and 4% for hypoesthesia [94]. An imme-
diate complete loss of vision in one eye after trigeminal
radiofrequency rhizotomy was reported in three patients due
to acute traumatic optic neuropathy [95]. Moreover, there
were patients who have masseter weakness and paralysis,
keratitis and transient paralysis of cranial nerves III and
VI, diminished corneal reflex, dysesthesia, and anesthesia
dolorosa [96]. Nevertheless, MVD remains the best choice
and a useful alternative to carbamazepine in the treatment of
TN (Table 1).
3. Myofascial Pain Dysfunction Syndrome
Myofascial pain dysfunction syndrome (MPDS) is known
as a psychophysiological disease, which is associated with
muscular structure—in particular, the muscle of mastication
[97]. MPDS is a commonly observed phenomenon in the
medical, dental, and psychological sectors. MPDS is also
termed myalgia, myofasciitis, myogelosis, myofascial pain,
fibromyalgia, myofibrositis, and myofascial pain syndrome
(MPS). When it is mainly associated with temporomandibu-
lar join dysfunction, it is termed as myofascial pain dysfunc-
tion syndrome [98–100]. Although the terms myofascial and
musculoskeletal pain are used frequently and alternately, they
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are different. Basically, musculoskeletal pain encompasses
almost all types of pain observed at the muscular level, while
myofascial pain indicates a specific syndrome caused by the
presence of trigger points (TrPs) within the muscles or their
fascia [101].
The following factors play a significant role in the etiology
of MPDS: (1) trauma, which is divided into macro- and
microtraumas; the former includes contusions, sprains, and
strains, all of which may result in acute MPDS; the latter,
however, has a slower onset. Chronic repetitive overloading
or the further overuse of muscles may cause fatigue; (2)
mechanical causes, which can be a result of internal factors
such as having incorrect postures or external factors such as
having poor ergonomics, especially at work; (3) degenerative
causes due to aging where the degeneration of bones and
joints, loss of myofascial flexibility, and arthritis can occur;
(4) nerve root compression, which may cause irritation and
lead to sensitization to the spinal segment; (5) dental causes,
which include occlusal disharmony; (6) faulty dentures; (7)
dental extraction; and (8) other factors.
According to Svensson and Graven-Nielsen, 2001 [102],
MPDS is defined as a stress-related disorder. It is assumed
that increased muscle tension, commonly combined with the
existence of some parafunctional habits (such as clenching or
grinding of teeth), results inmuscle fatigue and spasms highly
responsible for the pain experienced aswell as themandibular
dysfunction. However, it may also occur as a consequence of
muscular overextension, muscle overcontraction or trauma
in some rare cases [103, 104].
Myofascial pain syndrome is defined as a disorder that is
associated with pain arising from TrPs within the myofascial
structures, the pain appearing either locally or distant from
the affected region.On the other hand, TrPs are sensitive areas
in a muscle that continuously (or upon compression) cause
pain to a distant region [99, 105]. Alternatively, it can also be
described as a confined tender area in a firm band of skeletal
muscle, tendon, or ligament. These points can arise in any
skeletal muscle, occurring most repeatedly in the head and
neck, shoulders, and lower back [99].
3.1. Epidemiology. MPDS appears with muscular pain and
regional symptoms [106, 107] with a 30% percent occurrence,
thus contributing to considerable disability and inability to
work [108, 109]. It has been reported that, in the American
population, approximately 44million people have myofascial
pain-associated problems [110]. A statement from specialized
clinics for head and neck pain stated that 55% of cases
are related to myofascial etiology, while 95% of cases have
myofascial pain [111]. According to the same study (𝑛 = 164),
55% of patients diagnosed with myofascial pain also have
chronic head and neck pain for a minimum of six months
[112]. A Danish researcher reported the existence of myofas-
cial pain in 37%ofmen and 65%ofwomenwithin a randomly
selected population (𝑛 = 1504) aged between 30 and 60
years [113]. The Myofascial Pain Management Center at the
University of Miami School of Medicine conducted a study
in an American population (𝑛 = 283) and reported that 85%
of the cases primarily presented with MFP syndrome [114].
Another study stated that 74% of the patients had pain due
to a primary cause (such as mechanical cause), while 93%
complained of pain during the diagnosis. The data indicate
that a high proportion of patients are unaware of their disease,
with 74% of patients attending the clinic with pain that is
purported to be caused by eithermechanical injury or trauma
[112].
Another study reported that females tend to experience
a higher recurrence rate of MPDS than males, with the
male : female proportion ranging from 3 : 1 to 5 : 1 in various
reports [115]. The age group showing the highest incidence
was the 20- to 40-year age group, although children can
also have MPD syndrome [116]. The mean prevalence of
pain amongmiddle-aged to advanced-age individuals (30–60
years) is 37% for males and 65% for females. In advanced-
aged patients (>65 years), the prevalence can be as high as
85%. As a result, based on the demographics of aging, MPS
can most likely convert to one of the major problems in the
general population in the future [101].
3.2. Pathophysiology. The origin of TrPs in MFP syndrome is
still unknown, although there has been significant progress
in the identification of the features of TrPs [117, 118]. Pre-
cipitating factors of MFP (such as nerve root compression
and degenerative cause) have been hypothesized to lead to
the discharge of acetylcholine at motor end plates [119], thus
causing muscle fiber contractions. The release of vascular
and neuroactive substances causes local ischemia and also
aggravates muscular pain. Further acetylcholine discharge
can propagate the muscle pain and spasm. After a prolonged
period of time, local muscle fibrosis can occur [119, 120]. The
myofascial trigger point (MTrP) contains a neurovascular
bundle that consists of motor nerve endings and groups III
and IV nociceptive sensory afferent nerve endings [121, 122].
Triggering the nerve can lead to the sensory and motor
phenomena. In sensory phenomena, examined the nocicep-
tive process in myofascial TrP pain in chronic tension-type
headaches with 40 cases compared with 40 healthy controls.
The pressure in MTrP showed a linear relationship with
incremental pain, while the normal muscle tended to show a
nonlinear relationship. Some mechanisms in the spinal cord
that are associated with dysfunctional endplates in response
to sensitized sensory nerve fibers may also be involved. The
linear pattern of pain indicates that referred pain may occur
in response to stimulation of MTrP compared with the nor-
mal muscle [123]. On the other hand, in motor phenomena,
pathophysiological marker-needle electromyography (EMG)
activity has been identified within the 1 to 2mm nidus
of MTrP. In 1986, Laskin and Block hypothesized that the
source of electrical activity was intrafusal fibers inside the
muscle spindle [103]. However, Greene proposed a standard
hypothesis about dysfunctional motor endplates in 2001.
According to them, such electrical activity is demonstrated
in the endplate zone outside of MTrP [97].
3.3. Clinical Manifestation. MPDS is characterized by a dull,
aching, radiating pain and is more acute in jaw movement
(Figure 2). In the case of mandibular dysfunction, MPDS
causes limitation in mouth opening [124, 125]. Almost 70%
of patients complain of pain and tenderness around their
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MPDS
Clinical features
Dull and aching type pain
Unilateral and radiating
Diminished hearing
Radiological investigations
(i) CT scan
(ii) MRI
(iii) Scintigraphy 
Tenderness around TMJ
Clicking sound in TMJ
Trigger point present
Diagnostic tools 
Laboratory investigations
(i) FBC
(ii) Serum calcium
(iii) Alkaline phosphatase
(iv) Serum creatinine 
(v) ESR
Figure 2: Commonly used diagnostic tools and features of myofascial pain dysfunction syndrome (MPDS).
temporomandibular joints. Some patients also reported the
presence of a clicking sound or cracking noises in the tem-
poromandibular joint (TMJ) [124]. MPDS usually involves
only the face unilaterally. Frequent headache is also a com-
mon complaint (23% of cases). Only tension headaches may
be directly or indirectly associated with this syndrome. In
addition, a patient may also complain of diminished hearing,
tinnitus, burning tongue, and neuralgic pains. MPDS also
leads to some functional disorders and may cause organic
variations in the temporomandibular joint as well as in
masticatory muscles [103, 125]. Usually, the patient shows
pain in the trigger area when approximately 3 kg of pressure
is applied. The fibers show the local twitch response (LTR)
during plucking palpation inside the band of muscle [107].
3.4. Diagnostic Criteria. Myofascial pain syndrome is asso-
ciated with MTrPs and can be reproduced by firm palpation
over the trigger zone. The diagnostic features for myofascial
trigger points include the following:
(i) Upon palpation of the muscle, a focal point of tender-
ness may be found.
(ii) Trigger point palpation leads to a reproduction of the
pain.
(iii) There is a “taut band” in adjacent muscle.
(iv) There is restriction of muscle movement.
(v) It may appear with pseudo-weakness of the muscle
fiber.
(vi) Paresthesia occurs over the muscle area.
The diagnosis of MFP syndrome may be a challenge because
it shows some complex clinical characteristics. Most patients
tend to show some tenderness (67%) of the elevator muscles
during palpation. Nearly 40% of the patients’ complain of
pain on chewing. Thus, 30% have significant myalgia with
bruxism [126]. Sometimes, the patients may also complain of
sleep disturbance because the sleeping position may act as an
aggravating factor to the pain caused by MTrP [107].
Arthrography is a useful procedure for the diagnosis of
MPDS when the TMJ is involved. Radiographic interpreta-
tions of the head and neck region, CT scans and scintigraphy,
can also help to establish the concluding diagnosis. In this
case, MRI is indicated to allow better view of the condyle and
disc position of TMJ specifically. Sometimes laboratory tests
such as a complete blood count (in the case of suspected infec-
tion), serum calcium, phosphorus, and alkaline phosphatase
(for bone disorder) need to be investigated. Serum uric acid
(for gout), serum creatinine, and phosphokinase levels help
as useful indicators of muscular disorders. If rheumatoid
arthritis is suspected, the electrolyte sedimentation rate (ESR)
and rheumatoid factors should be investigated. Additionally,
electromyography can be used to assess muscle function and
fatigue. However, psychologic evaluation and psychometric
testing may also help in the diagnosis [127].
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3.5. Treatment and Management. Patient counseling regard-
ing the disease is very important. Usually, it is often difficult
for patients to accept a psychophysiologic explanation for
their diseases. Connecting the symptoms to specific masti-
catory muscles can facilitate the determination of the actual
cause of the type and location of pain. In cases of the involve-
ment of the temporal muscle, patients may suffer where
headache and jaw ache are common in the masseter and
pterygoid muscles, showing discomfort during swallowing
and earache associated with the lateral pterygoid muscle
[128].
Normally, injection is the first treatment approach in
the treatment of MPDS. An injection using dry needling
and lidocaine anesthetic solution injection may be helpful
in MPDS treatment. In 2010, Ay et al. [129] reported that
using dry needling and lidocaine injection with stretching
exercises may show a momentous role in the treatment of
MFP syndrome. Besides, botulinum toxin injection has been
reported to produce significant effects such as sudden pain
reduction, especially when a saline injection is not effective
[130–132].Moreover,Gazi et al. (2010) compared the analgesic
result of acupuncture (which is purported to help restore
blood circulation) to TrPs injections (containing 0.25% bupi-
vacaine administered twice weekly) with cyclobenzaprine
chlorhydrate and sodium dipyrone on trigger points to
prevent the recurrence ofMFP symptoms.The results showed
comparable pain liberation and progress in the quality of life
at 4 weeks [133]. Additionally, therapeutic ultrasound is a new
treatment strategy for MFP syndrome. Because it is a non-
invasive procedure, it is valuable in the treatment of deeper
muscle. Manual therapeutic techniques are not sufficient for
the assessment of deep muscle [134]. Other approaches have
been used in the treatment and management of MPDS
including psychotherapy [135, 136], home therapies [137],
medications [138, 139], and dental management [140, 141].
Sequential treatment is needed to manage such pain syn-
drome (Table 2).
3.6. Complications. In the case of a misdiagnosis, chronic
pain syndrome and complex behavioral problemsmay result,
leading to psychosocial problems. Most of the time, chronic
painmay cause sleep disturbance where patients have trouble
finding a comfortable sleeping position. Sometimes, posture
changes during sleepmay affect the disease, thus affecting the
patients’ sleep throughout the night [108].
4. Glossopharyngeal Neuralgia
Glossopharyngeal neuralgia (GPN) is a very sporadic condi-
tion related to hyperactivity of the glossopharyngeal nerve
[142]. GPN is rare compared with TN. The pain affects the
sensory areas corresponding to the glossopharyngeal neural-
gia with a branch of sensory vagus nerves. GPN consists of
spasmodic, momentary, and severe sharp pain in the poste-
rior area of the throat, tonsillar fossa, base of the tongue, ear
canal, and areas inferior to the angle of the mandible [143].
Generally, the pain persists for seconds to minutes and is
often triggered by chewing, coughing, yawning, talking, and
swallowing [144]. The prevalence of GPN is estimated to be
approximately 0.8 per 100,000 populations in a year, indicat-
ing that it is less common than TN (4.7 cases per 100,00) [26].
GPN is usually represented by a painful condition on the left
side of the body in females, whereas TN is more commonly
observed on the right side [145].
GPN is a mixture of cranial nerves that have somatic
sensory fibers from the oropharynx, mastoid, middle ear,
and Eustachian tube, and posterior third of the tongue. The
middle ear and mastoid have a sensory supply of glossopha-
ryngeal nerve along with the tympanic branch or Jacobson’s
nerve [146]. It also receives special sensory fibers for taste as
well as chemoreceptor and baroreceptor afferent input from
the carotid body and carotid sinus. Stylopharyngeus muscles
are supplied by the motor component, and the parotid gland
is supplied by the parasympathetic secretomotor supply. The
nerve of Hering is an important branch of the carotid sinus
branch, which conveys chemoreceptor and baroreceptor
information centrally for circulatory reflux function andmay
be accountable for the arrhythmogenicity of GPN [146, 147].
GPN is classified according to HIS, based on the involved
structural areas.The proposed classification of IHS is (1) clas-
sical GPN (occasional or episodic pain) and (2) symptomatic
GPN (constant pain) [58]. The classification is based on the
areas involved in otitis, that is, pain in (or around) the auricle
or earlobe. On the other hand, for the oropharyngeal type,
the pain is in and around the neck as well as the maxillofacial
regions. Nevertheless, these areas significantly overlap with
other cranial nerve-supplied areas [148].
GPN may be idiopathic with the absence of any obvious
lesion. Most cases are mainly recognized as glossopharyngeal
nerve compression triggered by a vessel at the root entry zone
of the brainstem [148, 149]. Idiopathic causes may be vascular
decompression and/or central pontine dysfunction. The sec-
ondary cause is a noticeable lesion that includes trauma (skull
base fracture, penetrating injury), postradiation, neoplasm
(skull base, cerebellopontine, brainstem, pharynx, tongue,
tonsil, metastatic head, and neck tumors), infection (tonsil-
litis, pharyngitis, petrositis, arachnoiditis, para pharyngeal
abscess, and tuberculosis), surgery (posttonsillectomy, post-
neck dissection, and postcraniotomy), vascular malforma-
tions (arteriovenous malformation, fusiform aneurisms, per-
sistent hypoglossal artery, and dissection of the vertebral
artery), demyelination (MS), and Eagle’s syndrome as well as
others which include direct carotid puncture, choroid plexus
overgrowth, and hyperactive dysfunction syndrome. This
type of GPN is usually accompanied with numbness or pain
around the affected area [150].
4.1. Clinical Manifestation. There are paroxysmal attacks of
facial pain, which last for seconds to minutes (Table 3). The
characteristics of pain are unilateral sharp, stabbing, and
severe shooting pain. The distribution of pain is persistent
within the posterior part of the tongue, pharynx to inner
angle of the lower jaw, and tonsillar fossa [151]. Pain occurs
within a certain interval with most occurring after a long
time, although some patients may experience it within a day
[152, 153].
The common trigger factors are swallowing, chewing,
talking, coughing, yawning, lateral movement of the jaw,
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Table 4: Radiological criteria in the diagnosis of TN, MPDS, and GPN.
Diseases Imaging (CT/MRI)
TN
Vascular compression of the trigeminal nerve (root entry zone) (demyelination and remyelination)
MS plaque (dorsal root entry zone)
Trigeminal ganglion (degenerative hypermyelination and microneuromata)
MPDS Condyle and disc position of TMJ
GPN Vascular compression of the glossopharyngeal nerve (root entry zone)
cleaning of the throat, tinnitus, sudden movement of the
head, touching the periodontium, and touching the external
surface of the ear. GPN is not attributed to other disorders
but may be related to vascular malformation, oropharyngeal
tumor, cerebellopontine angle masses, Chiari type I disorder,
multiple sclerosis, or TN [144, 154–158]. GPN may be not
found during an early screening or examination [159]. In
fact, GPN is often confused with Jacobson’s neuralgia during
clinical examination [160].
4.2. Diagnostic Criteria. GPN should be diagnosed by clinical
examinations. Patients usually experience unilateral stabbing
pain in the throat. The characteristics of pain and trigger
factors are helpful to confirm GPN. Neuralgic pain is severe,
episodic, and radiating for intervals compared with inflam-
matory pain. Inflammatory pain is persistent in nature,
lasting for minutes. The distribution of pain should be deter-
mined to ascertain the involvement of the glossopharyngeal
nerve or its association with other cranial nerves.
Classical GPN is mainly tympanic or posttonsillar pain
with a history of surgery. Distribution of the trigger point
is within the auricular, oropharyngeal area or can be trig-
gered by swallowing, talking or hearing. Lignocaine (2%) or
bupivacaine (0.5%) injection into the area close to the trigger
point may be helpful for the identification of otologic pain.
A complete history including trauma, radiotherapy, post-
surgery, inflammation or pathology related to the oral and
maxillofacial areas is useful to elucidate the cause of sec-
ondary GPN [161, 162].
Laboratory test including erythrocyte sedimentation rate
(ESR), serum chemistry, complete blood count, and anti-
nuclear antibody is helpful to determine if infection, inflam-
mation, and neoplastic malignancy occur. To determine if
vascular compression, any malignancy, or hard tissue change
has occurred, magnetic resonance angiography (MRA) and
3D CT-angiography, magnetic resonance imaging (MRI) can
be useful [163, 164]. These imaging techniques may help elu-
cidate vascular compression by identifying the origin of the
posterior inferior cerebellar artery since the posterior inferior
cerebellar artery makes an upward loop and compresses the
supraolivary fossette [165, 166]. If the offending vessel is the
anterior inferior cerebellar artery, the diagnosis of GPN is a
challenge without surgery [167]. GPN secondary to Eagle’s
syndrome is identified by a panoramic radiograph [168].
4.3. Treatment and Management. Nonsurgical pharmaco-
therapy is the treatment of choice for most of the cases
(Table 3). Failure of pharmacotherapy treatment, where the
nerve is compressed, can prompt the physician to opt for
surgery.
4.3.1. Nonsurgical Pharmacotherapy Approach. Carbamaze-
pine, gabapentin, and pregabalin are first-line pharmaco-
logical treatments for GPN. Vitamin B12 and a low-dose
selective serotonin reuptake inhibitor such as paroxetine
(20–50mg/day) or sertraline (50–200mg/day) are also help-
ful. A long-term nonsteroidal anti-inflammatory drug is not
recommended as long as the activity resulting in the inflam-
matory process can be reduced for treating GPN [169].
Opioids can be used, although they have been reported to
provide no additional benefit [170]. If pain relief cannot be
achieved, different medications such as baclofen and dex-
tromethorphan can be used.The combination of two or mul-
tiple agents is effective with physical therapy or psychological
treatment [171].
(1) Nerve Block. A glossopharyngeal nerve block is an excel-
lent adjunct to the pharmacological treatment of GPN for
rapid pain. A nerve block can be performed using a local
anesthetic agent such as lignocaine (2%) and bupivacaine
(0.5%) with or without steroids, ketamine, phenol, glycerol,
and alcohol. A nerve block can be performed either as
an intra- or extraoral approach. The extraoral approach is
preferred, as it is simpler andmore comfortable to the patient
[172, 173]. Difficulties in deglutition and huskiness of voice
can be an unwanted consequence of a glossopharyngeal nerve
block. In addition, a bilateral nerve block can cause the
paralysis of the vocal cord [172, 174].
4.3.2. Surgical Approach. There are several surgical proce-
dures offered such as direct surgical neurotomies or per-
cutaneous radiofrequency thermal rhizotomy [173], direct
sectioning of the nerve in the cerebellopontine angle [175], or
open trigeminal tractotomy-nucleotomy or nucleus caudalis
operations. The microvascular decompression (MVD) of
vascular roots and the rhizotomy of nerve roots are the
best options for surgical treatment. Vascular compression is
well recovered by MVD. Normally, intracranial root section
is widely considered when MVD is not possible [151, 176].
Through the improvement of microsurgical and anesthesi-
ology techniques, MVD has been established as an effective
and safe treatment option for drug-resistant GPN [175]. Over
76% of the cases showed improvement with MVD [162].
Extracranial neurotomy and percutaneous radiofrequency
rhizotomy are not commonly performed, and their applica-
tion is limited to drug-resistant GPN. Stylectomy is usually
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conducted for Eagle’s syndrome after ruling out the primary
cause of GPN [177, 178]. Pulsed radiofrequency neurolysis,
gamma-knife surgery, and stereotactic radiosurgery have also
shown beneficial effects in both idiopathic and secondary
GPN [148, 179].
5. Conclusion and Future Perspective
This review has outlined the current knowledge of the patho-
physiology, diagnostic criteria, and treatment of three com-
mon neuralgic maxillofacial pain syndromes. TN, GPN, and
MPDS can present with common signs. Hence, the appro-
priate use of definite diagnostic measures is significant to
support the differential diagnosis. Severe and diffuse pain can
obscure the diagnosis, possibly leading to an inappropriate
finding or an incorrect diagnosis. Precise diagnostic criteria
will facilitate clear diagnoses and the framing of good treat-
ment plans for a proper therapeutic schedule. Various phar-
macological and surgical treatment options have been used
with varying success rates andmorbidities.There is a need for
further research into the management of neuralgic maxillo-
facial pain with appropriately designed treatment strategies.
A multidisciplinary team is frequently essential for the diag-
nosis and management of many maxillofacial painful condi-
tions.
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